PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The in vivo imaging probe [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(4'-methylaminophenyl-6-hydroxybenzathiazole) is under evaluation as a key imaging tool in Alzheimer's disease (AD) and to date has been assumed to bind with high affinity and specificity to the amyloid structures associated with classical plaques (CPs), one of the pathological hallmarks of the disease. However, no studies have systematically investigated PIB binding to human neuropathological brain specimens at the tracer concentrations achieved during in vivo imaging scans. Using a combination of autoradiography and histochemical techniques, we demonstrate that PIB, in addition to binding CPs clearly delineates diffuse plaques and cerebrovascular amyloid angiopathy (CAA). The interaction of PIB with CAA was not fully displaceable and this may be linked to the apolipoprotein E-epsilon4 allele. PIB was also found to label neurofibrillary tangles, although the overall intensity of this binding was markedly lower than that associated with the amyloid-beta (Abeta) pathology. The data provide a molecular explanation for PIB's limited specificity in diagnosing and monitoring disease progression in AD and instead indicate that the ligand is primarily a non-specific marker of Abeta-peptide related cerebral amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Images of adjacent MFG sections from two Category A pathology cases (A1in A^C ; A2 in D^G ), showing correspondence of [3H]-PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining artefacts on 6E10 sections. Higher power representative images of boxed area from case A2 arranged in consecutive cryostat order ( G ). Selected corresponding pathological features are highlighted in pink (DPs), orange (CPs) and blue (CAA). Scale bar 1mm.](https://figures.cochat.ai/paper-figures/53cf42bb40d34aaf9b53cf4f09ffbcbc/pib-is-a-non-specific-imaging-marker-of-amyloid-beta-a-peptide-related-cerebral-figure-1.png)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pittsburgh Compound B retention is not specific for CAA as opposed to Alzheimer disease, because the compound binds to both vascular and parenchymal amyloid158; however, the 2 pathologies may be distinguishable in part by the relative occipital predominance of labeling in CAA.156,157”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [158]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 5×
“…vivo observations with data from both the large number of antecedent postmortem studies detailing the regional, microscopic spread of AD pathology (Braak and Braak, 1991a; Berg et al., 1998; Price and Morris, 1999) and the relatively sparse literature characterizing the interaction of imaging…”
BackgroundMethodInfluentialMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 5×
“Additionally, an inverse correlation of PIB retention with the pattern of decreased regional cerebral glucose metabolism rate (rCMRglc) has been observed (Klunk et al., 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007).”
BackgroundResultInfluentialConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 3×
“…retention of [11C]-PIB in brain regions not normally associated with a high CP load such as the striatum and frontal cortex (Klunk et al., 2004; Nordberg, 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007) cannot readily be explained by the reported specificity of PIB for CPs.”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents
Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 979 · cited 1×
“…protocols used in this study differ significantly from the previous studies investigating the interaction of PIB with human brain sections (Klunk et al., 2003; Mathis et al., 2003, 2004; Bacskai et al., 2007) and that these may explain the novel findings associated with the current study.”
Alzheimer’s amyloid fibrils: structure and assembly
Serpell, L. C. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00029-6 · Cited by 959 · cited 1×
“Both Ab, which forms the fibrils variably associated with SPs (and cerebrovascular amyloid), and tau, which forms the paired helical and straight filaments associated with NFTs, are types of amyloid (Serpell, 2000; Berriman et al., 2003; Barghorn et al., 2004).”
Background
Research works printed but not linked: 3
- Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothia- zoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
- Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52.
- Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-12.
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
“…compound B (PIB) primarily measure brain amyloid plaque load (Klunk et al ., 2004; Rowe et al ., 2007; Drzezga et al ., 2008; Ikonomovic et al ., 2008; Leinonen et al ., 2008) but also localize in cerebral vascular amyloid (Bacskai et al ., 2007; Johnson et al ., 2007; Lockhart et al ., 2007).”
Frequent amyloid deposition without significant cognitive impairment among the elderly
Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059
Classification and basic pathology of Alzheimer disease
Duyckaerts, C., Delatour, B., & Potier, M.-C. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0532-1 · Cited by 1,031
“deposits indeed bind PIB although not specifically [207].”
BackgroundAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
“study (Lockhart et al., 2007), some N-terminus Ab truncated diffuse Ab plaques in the ERC could have gone undetected by the N-terminus Ab IHC and thioflavin-S histochemistry.”
BackgroundInfluentialBrain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
“Along similar lines, cerebrovascular amyloid typically has a high degree of fibrillar Ab and appears to be a very good substrate for amyloid tracer binding (Bacskai et al. 2007; Johnson et al. 2007; Lockhart et al. 2007; Ikonomovic et al. 2008).”
BackgroundAPOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671
Episodic memory loss is related to hippocampal-mediated -amyloid deposition in elderly subjects
Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., Koeppe, R. A., Mathis, C. A., Weiner, M. W., Jagust, W. J., et al. (2009) · Brain · doi:10.1093/brain/awn320 · Cited by 684
“A further possibility is that global Ab plaque quantities may be a marker of soluble Ab levels, which are undetected with PIB-PET imaging (Lockhart et al., 2007).”
BackgroundKoronyo-Hamaoui, M., Koronyo, Y., Ljubimov, A. V., Miller, C. A., Ko, M. K., Black, K. L., Schwartz, M., & Farkas, D. L. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.020 · Cited by 672
“However, such noninvasive monitoring of Aβ plaques is still clinically challenging, and is of limited resolution and availability (Klunk et al., 2005; Lockhart et al., 2007; Toyama et al., 2005).”
18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 646
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
“PET using tracers for Aβ is thought to represent accumulation of the pathognomonic sign of Alzheimer's disease, that is, Aβ plaque”
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460
Self-citationImaging amyloid deposition in Lewy body diseases
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326146.60732.d6 · Cited by 443
Edison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N., Villemagne, V. L., O'Keefe, G., Nagren, K., Chaudhury, K. R., et al. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.127878 · Cited by 431
Villeneuve, S., Rabinovici, G. D., Cohn-Sheehy, B. I., Madison, C., Ayakta, N., Ghosh, P. M., La Joie, R., Arthur-Bentil, S. K., Vogel, J. W., Marks, S. M., et al. (2015) · Brain · doi:10.1093/brain/awv112 · Cited by 408
Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387
“Amyloid neuroimaging has made it possible to identify amyloid deposition in vivo (Klunk et al., 2004) and recent studies have suggested that Pittsburgh compound B binds to fibrillar amyloid-b deposits (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundAmyloid‐β associated cortical thinning in clinically normal elderly
Becker, J. A., Hedden, T., Carmasin, J., Maye, J., Rentz, D. M., Putcha, D., Fischl, B., Greve, D. N., Marshall, G. A., Salloway, S., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22333 · Cited by 342
Nelissen, N., Van Laere, K., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M., Bormans, G., Brooks, D. J., & Vandenberghe, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 330
“At the low or subnanomolar administered concentrations of PET ligands in vivo, PiB does not bind to neurofibrillary tangles (2, 10 )o ra-synuclein fibrils (12).”
BackgroundCheng, K. K., Yeung, C. F., Ho, S. W., Chow, S. F., Chow, A. H. L., & Baum, L. (2013) · The AAPS Journal · doi:10.1208/s12248-012-9444-4 · Cited by 314
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324
“, 1991), both of which have fibrillar forms of amyloid that bind the fluorescent analogue of PiB or radiolabelled PiB (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundMethodInfluentialStorandt, M., Mintun, M. A., Head, D., & Morris, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.272 · Cited by 304
Cheng, K. K., Chan, P. S., Fan, S., Kwan, S. M., Yeung, K. L., Wáng, Y.-X. J., Chow, A. H. L., Wu, E. X., & Baum, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.005 · Cited by 293
Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., Ackermann, U., Cowie, T. F., Currie, J., Chan, S. G., et al. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.02.008 · Cited by 292
Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging
Mosconi, L., Berti, V., Glodzik, L., Pupi, A., De Santi, S., & de Leon, M. J. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091504 · Cited by 277
β-Amyloid, Blood Vessels, and Brain Function
Smith, E. E., & Greenberg, S. M. (2009) · Stroke · doi:10.1161/strokeaha.108.536839 · Cited by 293
Rabinovici, G. D., Furst, A. J., Alkalay, A., Racine, C. A., O’Neil, J. P., Janabi, M., Baker, S. L., Agarwal, N., Bonasera, S. J., Mormino, E. C., et al. (2010) · Brain · doi:10.1093/brain/awp326 · Cited by 280
“Differences between early-onset and late-onset Alzheimer’s disease may also be explained by a differential burden of neurofibrillary tangles, which do not appreciably bind PIB at PET tracer concentrations (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundGrimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278
Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
Minati, L., Edginton, T., Grazia Bruzzone, M., & Giaccone, G. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 268
Brickman, A. M., Zahodne, L. B., Guzman, V. A., Narkhede, A., Meier, I. B., Griffith, E. Y., Provenzano, F. A., Schupf, N., Manly, J. J., Stern, Y., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.019 · Cited by 255
“White matter hyperintensities are typically considered to be a nonspecific marker of cerebrovascular diseases associated with aging and not AD specifically, but beta amyloid and tau pathology can be described similarly; both are common in aging and certainly occur among older adults without any clinical evidence of ne…”
BackgroundEffect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e8d0 · Cited by 248
Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP
Doran, E., Keator, D., Head, E., Phelan, M. J., Kim, R., Totoiu, M., Barrio, J. R., Small, G. W., Potkin, S. G., & Lott, I. T. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160836 · Cited by 244
“However, they do not address the absolute 496 affinity of PiB for A peptide [60].”
Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations
Yates, P. A., Villemagne, V. L., Ellis, K. A., Desmond, P. M., Masters, C. L., & Rowe, C. C. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2013.00205 · Cited by 231
“PiB can also highlight presence of β-amyloid in cerebral vessel walls, even in the absence of parenchymal plaques, both in vitro (88) and in vivo with subsequent post-mortem follow-up (89, 90).”
BackgroundAmyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo
Rabinovici, G. D., & Jagust, W. J. (2009) · Behavioural Neurology · doi:10.1155/2009/609839 · Cited by 185
Biomarkers for the Early Detection and Progression of Alzheimer's Disease
Counts, S. E., Ikonomovic, M. D., Mercado, N., Vega, I. E., & Mufson, E. J. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0481-z · Cited by 224
The benzazole scaffold: a SWAT to combat Alzheimer's disease
Noël, S., Cadet, S., Gras, E., & Hureau, C. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60086f · Cited by 214
Does Alzheimer's disease begin in the brainstem?
Simic, G., Stanic, G., Mladinov, M., Jovanov‐Milosevic, N., Kostovic, I., & Hof, P. R. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2009.01038.x · Cited by 204
“Diffuse deposits of b-amyloid have been found in large numbers even in subjects whose intellectual status had been evaluated as normal both neuropathologically [6] and by in vivo visualization using Pittsburgh compound B positron emission tomography (PIB PET, see below) [ 7 ].”
MethodKoronyo, Y., Salumbides, B. C., Black, K. L., & Koronyo-Hamaoui, M. (2012) · Neurodegenerative Diseases · doi:10.1159/000335154 · Cited by 196
Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., Guzman, V. A., Meier, I. B., Zimmerman, M. E., Brickman, A. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1321 · Cited by 192
PET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 174
The pattern of amyloid accumulation in the brains of adults with Down syndrome
Annus, T., Wilson, L. R., Hong, Y. T., Acosta–Cabronero, J., Fryer, T. D., Cardenas–Blanco, A., Smith, R., Boros, I., Coles, J. P., Aigbirhio, F. I., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.07.490 · Cited by 182
Optical Coherence Tomography in Alzheimer’s Disease and Other Neurodegenerative Diseases
Doustar, J., Torbati, T., Black, K. L., Koronyo, Y., & Koronyo-Hamaoui, M. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00701 · Cited by 176
Multimodality imaging characteristics of dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Boeve, B. F., Weigand, S. D., Senjem, M. L., Przybelski, S. A., Dickson, D. W., Parisi, J. E., Knopman, D. S., Smith, G. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.024 · Cited by 174
Bartels, A. L., Kortekaas, R., Bart, J., Willemsen, A. T. M., de Klerk, O. L., de Vries, J. J., van Oostrom, J. C. H., & Leenders, K. L. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.02.002 · Cited by 158
“However, PIB is also reported to be a nonpecific marker of A -related cerebral amyloidosis, rather han a specific A -plaque marker (Lockhart et al., 2007); nd binding in white matter might thus also be related to hite matter vascular changes with amyloid disposition.”
BackgroundPET imaging of brain amyloid in dementia: a review
Quigley, H., Colloby, S. J., & O'Brien, J. T. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2640 · Cited by 150
“In vitro, PIB has been shown to bind specifically to extracellular and intravascular fibrillar Ab deposits in post mortemAD brains (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundCognition, glucose metabolism and amyloid burden in Alzheimer's disease
Furst, A. J., Rabinovici, G. D., Rostomian, A. H., Steed, T., Alkalay, A., Racine, C., Miller, B. L., & Jagust, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.011 · Cited by 144
“PIB uptake generally correlates well with post-mortem levels of Aβ deposits (Bacskai et al., 2007; Ikonomovic et al., 2008; Lockhart et al., 2007) and has also been shown to closely reflect Aβ pathology in vivo (Leinonen et al.”
BackgroundContemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities
Brickman, A. M. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0415-7 · Cited by 141
Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand
Juréus, A., Swahn, B., Sandell, J., Jeppsson, F., Johnson, A. E., Johnström, P., Neelissen, J. A. M., Sunnemark, D., Farde, L., & Svensson, S. P. S. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06812.x · Cited by 141
“This is in accordance with previously data showing that thioflavin-type PET tracers are non-specific for Ab insoluble deposits (i.e., diffuse, fibrillar or dense core and vascular plaques) (Lockhart et al. 2007).”
BackgroundResultKadir, A., Marutle, A., Gonzalez, D., Schöll, M., Almkvist, O., Mousavi, M., Mustafiz, T., Darreh-Shori, T., Nennesmo, I., & Nordberg, A. (2011) · Brain · doi:10.1093/brain/awq349 · Cited by 140
“Similar results have been obtained in in vitro studies with PIB binding to synthetic Ab fibrils and insoluble Ab deposits in human post-mortem brain tissues (Klunk et al., 2005; Bacskai et al., 2007; Lockhart et al., 2007; Ikonomovic et al., 2008; Cairns et al., 2009; Svedberg et al., 2009).”
BackgroundResultCerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 121
“vascular amyloid, which tends to be fibrillar, also binds PIB [6, 11, 37, 51, 66, 114].”
BackgroundAlzheimer’s Retinopathy: Seeing Disease in the Eyes
Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo-Hamaoui, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00921 · Cited by 128
“It consists of the light-sensitive neurosensory retina and retinal pigment epithelium (RPE).”
BackgroundInfluentialChoi, S. R., Schneider, J. A., Bennett, D. A., Beach, T. G., Bedell, B. J., Zehntner, S. P., Krautkramer, M. J., Kung, H. F., Skovronsky, D. M., Hefti, F., et al. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31821300bc · Cited by 129
Self-citationThal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134
“However, reagents like PIB are not specific for binding only on A deposits [135].”
BackgroundInteraction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies
Thompson, P. W., Ye, L., Morgenstern, J. L., Sue, L., Beach, T. G., Judd, D. J., Shipley, N. J., Libri, V., & Lockhart, A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05996.x · Cited by 137
“Previous studies indicated that (3)H-PIB associated with this specific Ab pool was only partially displaceable in labelling reactions containing excess unlabelled ligand (Lockhart et al. 2007).”
BackgroundMethodResultInfluentialSelf-citationWhen Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Klunk, W. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.006 · Cited by 129
“In addition, fibrillar Aβ can be found in varying degrees in plaques that have been loosely characterized as “diffuse”, and these diffuse plaques can be detected to some extent by amyloid imaging agents (Burack et al., 2010; Ikonomovic et al., 2008; Lockhart et al., 2007).”
BackgroundSmall-molecule PET Tracers for Imaging Proteinopathies
Mathis, C. A., Lopresti, B. J., Ikonomovic, M. D., & Klunk, W. E. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.06.003 · Cited by 123
Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy
Gurol, M. E., Dierksen, G., Betensky, R., Gidicsin, C., Halpin, A., Becker, A., Carmasin, J., Ayres, A., Schwab, K., Viswanathan, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826043a9 · Cited by 122
Manook, A., Yousefi, B. H., Willuweit, A., Platzer, S., Reder, S., Voss, A., Huisman, M., Settles, M., Neff, F., Velden, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031310 · Cited by 119
AZD2184: a radioligand for sensitive detection of β‐amyloid deposits
Johnson, A. E., Jeppsson, F., Sandell, J., Wensbo, D., Neelissen, J. A. M., Juréus, A., Ström, P., Norman, H., Farde, L., & Svensson, S. P. S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05861.x · Cited by 120
Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET
Tolboom, N., Yaqub, M., van der Flier, W. M., Boellaard, R., Luurtsema, G., Windhorst, A. D., Barkhof, F., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056499 · Cited by 119
“The differences in regional binding can be explained by the binding characteristics of 11C-PIB and 18F-FDDNP: the in vivo cortical uptake of 11C-PIB primarily reflects Ab-related cerebral amyloidosis ( 29 ), whereas uptake of 18F-FDDNP results from binding to both amyloid depositions and neurofibrillary tangles (30).”
BackgroundFörster, S., Grimmer, T., Miederer, I., Henriksen, G., Yousefi, B. H., Graner, P., Wester, H.-J., Förstl, H., Kurz, A., Dickerson, B. C., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.023 · Cited by 119
Sojkova, J., Driscoll, I., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletnikova, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 113
“Potential factors that may affect the relation between in vivo imaging and CERAD-based assessment of NPs fall into 3 broad categories: (1) those related to CERAD’s semiquantitative assessment of Aβ, (2) those related to different forms of Aβ, and (3) other factors, such as the imaging–pathologic assessment interval.”
Harada, R., Okamura, N., Furumoto, S., Tago, T., Maruyama, M., Higuchi, M., Yoshikawa, T., Arai, H., Iwata, R., Kudo, Y., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2261-2 · Cited by 108
“A previous study suggested that [(3)H]PiB labelled NFTs at tracer concentrations usually achieved during a PET scan [13].”
BackgroundCharacterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias
Fodero-Tavoletti, M. T., Rowe, C. C., McLean, C. A., Leone, L., Li, Q.-X., Masters, C. L., Cappai, R., & Villemagne, V. L. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057984 · Cited by 110
“In the absence of congophilic angiopathy, perivascular accumulation of PiB has been previously reported as representing either a nonspecific interaction (27, 28 )o r an artifact (28).”
Backgroundβ-Amyloid PET and neuropathology in dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Chen, Q., Przybelski, S. A., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Jack, C. R., Graff‐Radford, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008818 · Cited by 118
Grimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.013 · Cited by 101
Driscoll, I., Troncoso, J. C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, M. A., Ferrucci, L., Mathis, C. A., Klunk, W. E., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1025-1 · Cited by 104
“In vitro, (11)C-PiB binds specifically to extracellular and vascular fibrillar Ab [15, 23].”
BackgroundUsing Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
(2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 99
“A similar observation of PiB binding to CAA and classical and diffuse plaques was reported using [H-3]PiB autoradiography on brain tissue sections (Lockhart et al., 2007; Thompson et al., 2009).”
InfluentialCerebral small vessel disease and Alzheimer’s disease
Cai, Z., Wang, C., He, W., Tu, H., Tang, Z., Xiao, M., & Yan, L.-J. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s90871 · Cited by 98
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias
Villemagne, V. L., Fodero‐Tavoletti, M. T., Pike, K. E., Cappai, R., Masters, C. L., & Rowe, C. C. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8019-y · Cited by 118
“In a similar way that with α-synuclein fibrils [150], PiB binds to NFTs with comparatively lower affinity than Aβ [131], further”
High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimer’s Disease
Stukas, S. K., Robert, J., & Wellington, C. L. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.003 · Cited by 112
“2010), although the resolution of current techniques does not allow a clear distinction between parenchymal and vascular amyloid burden (Bacskai et al., 2007; Ikonomovic et al., 2008; Johnson et al., 2007; Lockhart et al., 2007).”
BackgroundCerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers
Soontornniyomkij, V., Moore, D. J., Gouaux, B. D., Soontornniyomkij, B., Tatro, E. T., Umlauf, A., Masliah, E., Levine, A. J., Singer, E. J., Vinters, H. V., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32835a117c · Cited by 106
“Due to its higher affinity to fibrillar Aβ compared to the affinity of thioflavin-S [44], PiB also marks diffuse Aβ plaques [41, 43], characteristically composed of small amounts of fibrillar Aβ [45].”
BackgroundCurrent Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies
Mistur, R., Mosconi, L., Santi, S. D., Guzman, M., Li, Y., Tsui, W., & de Leon, M. J. (2009) · Journal of Clinical Neurology · doi:10.3988/jcn.2009.5.4.153 · Cited by 93
Villemagne, V. L., Furumoto, S., Fodero-Tavoletti, M., Harada, R., Mulligan, R. S., Kudo, Y., Masters, C. L., Yanai, K., Rowe, C. C., & Okamura, N. (2012) · Future Neurology · doi:10.2217/fnl.12.34 · Cited by 97
Rosen, R. F., Walker, L. C., & LeVine, H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.02.011 · Cited by 97
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“There however remains debate about the pathological nature of diffuse as opposed to neuritic plaques (Masliah et al., 1990; Morris et al., 1996).”
BackgroundBiomarkers in dementia with Lewy bodies: a review
Sinha, N., Firbank, M., & O'Brien, J. T. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2749 · Cited by 101
“In vitro, PIB has been shown to bind specifically to extracellular and intravascular fibrillar Aβ deposits in post‐mortem AD brains (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundClinical severity of Alzheimer's disease is associated with PIB uptake in PET
Grimmer, T., Henriksen, G., Wester, H., Förstl, H., Klunk, W. E., Mathis, C. A., Kurz, A., & Drzezga, A. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.016 · Cited by 111
Detection of isolated cerebrovascular β‐amyloid with pittsburgh compound B
Greenberg, S. M., Grabowski, T., Gurol, M. E., Skehan, M. E., Nandigam, R. N. K., Becker, J. A., Garcia‐Alloza, M., Prada, C., Frosch, M. P., Rosand, J., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21528 · Cited by 96
Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights
Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 89
Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome
Neale, N., Padilla, C., Fonseca, L. M., Holland, T., & Zaman, S. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.10.022 · Cited by 86
Ye, L., Velasco, A., Fraser, G., Beach, T. G., Sue, L., Osredkar, T., Libri, V., Spillantini, M. G., Goedert, M., & Lockhart, A. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05245.x · Cited by 92
“In addition, this study provides further specific support to the observation that in vivo PIB is likely to be a non-disease specific imaging marker of Ab peptide-related cerebral amyloidosis (Lockhart et al. 2007).”
MethodResultInfluentialSelf-citationNeuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Lowe, V. J., Lundt, E. S., Albertson, S. M., Przybelski, S. A., Senjem, M. L., Parisi, J. E., Kantarci, K., Boeve, B., Jones, D. T., Knopman, D., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.016 · Cited by 90
Amyloid-β Positron Emission Tomography Imaging Probes: A Critical Review
Kepe, V., Moghbel, M. C., Långström, B., Zaidi, H., Vinters, H. V., Huang, S.-C., Satyamurthy, N., Doudet, D., Mishani, E., Cohen, R. M., et al. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130485 · Cited by 86
Wu, C. F., Bowers, M. T., & Shea, J. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2011.01.058 · Cited by 101
Molecular imaging in dementia: Past, present, and future
Laforce, R., Soucy, J., Sellami, L., Dallaire‐Théroux, C., Brunet, F., Bergeron, D., Miller, B. L., & Ossenkoppele, R. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.2855 · Cited by 88
Ikonomovic, M. D., Abrahamson, E. E., Price, J. C., Hamilton, R. L., Mathis, C. A., Paljug, W. R., Debnath, M. L., Cohen, A. D., Mizukami, K., DeKosky, S. T., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0943-2 · Cited by 85
“Several previous in vivo-postmortem PiB correlation studies are relevant to the interpretation of our findings (Table 1), and two studies of PiB binding and neuropathology in postmortem tissue without correlative in vivo [C-11]PiB PET data yield additional insights [27, 42].”
Svedberg, M. M., Hall, H., Hellström‐Lindahl, E., Estrada, S., Guan, Z.-Z., Nordberg, A. K., & Långström, B. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.016 · Cited by 93
Knight, W. D., Okello, A. A., Ryan, N. S., Turkheimer, F. E., Rodríguez Martinez de Llano, S., Edison, P., Douglas, J., Fox, N. C., Brooks, D. J., & Rossor, M. N. (2011) · Brain · doi:10.1093/brain/awq310 · Cited by 84
Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer’s disease
Rosen, R. F., Ciliax, B. J., Wingo, T. S., Gearing, M., Dooyema, J., Lah, J. J., Ghiso, J. A., LeVine, H., & Walker, L. C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0583-3 · Cited by 82
“Furthermore, PIB has been shown to be a sensitive marker for CAA in vivo [2, 11] and in vitro [19].”
BackgroundLaforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
Practical utility of amyloid and FDG-PET in an academic dementia center
Sánchez-Juan, P., Ghosh, P. M., Hagen, J., Gesierich, B., Henry, M., Grinberg, L. T., O'Neil, J. P., Janabi, M., Huang, E. J., Trojanowski, J. Q., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000032 · Cited by 78
Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting
Plissonneau, M., Pansieri, J., Heinrich, L., Morfin, J., Stransky-Heilkron, N., Rivory, P., Mowat, P., Dumoulin, M., Cohen, R., Allémann, É., et al. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0212-y · Cited by 79
“Although these peptides are described as β-breakers due to their ability to interact with Aβ monomer and to inhibit the formation of amyloid oligomers [56] and fibrils [36, 56, 57], they were shown to selectively interact with Aβ(1–42) amyloid fibrils as well.”
BackgroundAmyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease
Prvulovic, D., & Hampel, H. (2011) · cclm · doi:10.1515/cclm.2011.087 · Cited by 73
Beach, T. G., Sue, L. I., Walker, D. G., Sabbagh, M. N., Serrano, G., Dugger, B. N., Mariner, M., Yantos, K., Henry-Watson, J., Chiarolanza, G., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111340 · Cited by 74
Self-citation
Metadata
- Authors
- Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- University Hospital of Basel (CH)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 130
- Issue
- 10
- Pages
- 2607-2615
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2031309116
- Cited by
- 302
- References
- 55
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 15 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 13 · 2016: 15 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 35
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research (211002, P30 AG19610)
- GlaxoSmithKline
- Arizona Department of Health Services (P30 AG19610, 211002, Contract 211002)
- Arizona Biomedical Research Commission (P30 AG19610, contract 0011, 211002)
- National Institute on Aging (211002, P30-AG-19610, AG-19610, P30AG019610)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- Pittsburgh compound B, [11C]PIB, amyloid-beta, cerebral amyloidosis, Alzheimer's disease, diffuse plaques, neurofibrillary tangles, APOE ε4, autoradiography, amyloid imaging
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Brain, Carbon Radioisotopes, Humans, Thiazoles, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.